Literature DB >> 2748233

Intra-uterine cystography for evaluation of prenatal obstructive uropathy.

P Stoutenbeek1, T P de Jong, J D van Gool, A P Drogtrop.   

Abstract

To evaluate the risk for kidney damage in a male fetus with obstructive uropathy, a percutaneous bladder puncture was performed at 26 weeks gestational age and contrast was injected into the fetal bladder. A clear picture was obtained of the bladder with marked widening of the prostatic urethra and posterior urethral valves, and massive bilateral vesicoureteral reflux could be demonstrated. By adding cysto-urethrography to a diagnostic puncture of the fetal bladder it could be proved that the dilatation of the upper urinary tracts was caused by high-pressure vesico-ureteral reflux incurring progressive damage to the renal parenchyma.

Entities:  

Mesh:

Year:  1989        PMID: 2748233     DOI: 10.1007/bf02386845

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  5 in total

1.  The management of fetal urinary tract obstruction.

Authors:  Z Appelman; M S Golbus
Journal:  Clin Obstet Gynecol       Date:  1986-09       Impact factor: 2.190

2.  [Prenatal diagnosis of urinary tract malformations: therapeutic approach].

Authors:  C C Schulman; E F Avni; F Rodesch; A Pardou; D Detemmerman
Journal:  Rev Med Brux       Date:  1985-10

3.  Fetal urinary tract obstruction: is active intervention before delivery indicated?

Authors:  I R McFadyen; J S Wigglesworth; M J Dillon
Journal:  Br J Obstet Gynaecol       Date:  1983-04

4.  Management of the fetus with a urinary tract malformation.

Authors:  M R Harrison; R A Filly; J T Parer; M J Faer; J B Jacobson; A A de Lorimier
Journal:  JAMA       Date:  1981-08-07       Impact factor: 56.272

5.  Management of the fetus with congenital hydronephrosis II: Prognostic criteria and selection for treatment.

Authors:  P L Glick; M R Harrison; M S Golbus; N S Adzick; R A Filly; P W Callen; B S Mahony; R L Anderson; A A deLorimier
Journal:  J Pediatr Surg       Date:  1985-08       Impact factor: 2.545

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.